Development and efficacy test of a live, attenuated Mycoplasma hyorhinis vaccine candidate strain

Puntos clave

• Protection against mycoplasma hyorhinis infection was demonstrated with the attenuated vaccine strain.
• The vaccine candidate, combined with an adjuvant, shows promise for effective prevention.
• Observational analysis of infection rates indicates significant benefits from the vaccine.
• These findings suggest further development and testing in diverse settings may be warranted.